Vesencumab

Last updated April 08, 2019

It is proposed that this article be deleted because of the following concern:

nothing on PubMed

If you can address this concern by improving, copyediting, sourcing, renaming, or merging the page, please edit this page and do so. You may remove this message if you improve the article or otherwise object to deletion for any reason. Although not required, you are encouraged to explain why you object to the deletion, either in your edit summary or on the talk page. If this template is removed, do not replace it .

The article may be deleted if this message remains in place for seven days, i.e., after 17:39, 23 October 2018 (UTC).
If you created the article, please don't be offended. Instead, consider improving the article so that it is acceptable according to the deletion policy.

Nominator: Please consider notifying the author/project: {{subst:proposed deletion notify |Vesencumab|concern=nothing on PubMed}} ~~~~

Vesencumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	neuropilin 1
Clinical data
ATC code	none
Identifiers
CAS Number	1205533-60-3 ^N
ChemSpider	none
KEGG	D10494 ^N
Chemical and physical data
Formula	C₆₄₃₀H₉₉₄₈N₁₇₀₈O₂₀₁₆S₄₈
Molar mass	145.0 kg/mol
^NY (what is this?) (verify)

Vesencumab is an immunomodulator designed for the treatment of solid malignancies.^[1] It binds to neuropilin 1.^[2]

References

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Vesencumab, American Medical Association .
↑ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab ^§ Ascrinvacumab ^§ Cixutumumab ^§ Conatumumab ^§ Daratumumab Drozitumab ^§ Duligotumab ^§ Dusigitumab ^§ Enfortumab vedotin ^† Enoticumab ^§ Figitumumab ^§ Ganitumab ^† Glembatumumab vedotin ^† Intetumumab ^§ Ipilimumab Iratumumab ^§ Istiratumab Icrucumab ^§ Lexatumumab ^§ Lucatumumab ^§ Mapatumumab ^§ Narnatumab ^§ Necitumumab Nesvacumab ^§ Ofatumumab Olaratumab ^† Panitumumab Patritumab ^§ Pritumumab ^§ Radretumab ^§ Ramucirumab Rilotumumab ^† Robatumumab ^§ Seribantumab ^§ Tarextumab ^§ Teprotumumab ^† Tovetumab ^§ Vantictumab ^§ Vesencumab ^§ Votumumab ^§ Zalutumumab ^† "-melu-" (melanoma) Flanvotumab ^§
Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Lilotomab Minretumomab Mitumomab Moxetumomab pasudotox ^† Naptumomab estafenatox Nofetumomab merpentan Omburtamab Pemtumomab ^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox
Chimeric ("-tuxi-")	Amatuximab ^§ Bavituximab ^§ Brentuximab vedotin Carotuximab ^† Cetuximab Derlotuximab biotin ^§ Dinutuximab Ensituximab ^§ Futuximab ^§ Girentuximab ^† Indatuximab ravtansine ^§ Isatuximab ^† Loncastuximab tesirine Margetuximab ^† Rituximab ^# Siltuximab Ublituximab ^† "-mexi-" (melanoma): Ecromeximab ^§
Humanized ("-tuzu-")	Abituzumab ^§ Alemtuzumab Bemarituzumab ^† Bevacizumab Bivatuzumab mertansine ^§ Brontictuzumab ^§ Cantuzumab mertansine ^§ Cantuzumab ravtansine ^§ Cirmtuzumab Citatuzumab bogatox ^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab ^§ Demcizumab ^§ Dalotuzumab ^§ Denintuzumab mafodotin ^§ Elotuzumab Emactuzumab ^§ Emibetuzumab ^§ Enoblituzumab ^§ Etaracizumab ^§ Farletuzumab ^§ Ficlatuzumab ^§ Flotetuzumab ^§ Gemtuzumab ozogamicin ^‡ Imgatuzumab ^§ Inotuzumab ozogamicin ^† Labetuzumab ^§ Lifastuzumab vedotin ^§ Lintuzumab ^§ Lorvotuzumab mertansine ^§ Lumretuzumab ^§ Matuzumab ^§ Milatuzumab ^§ Nimotuzumab ^† Obinutuzumab Ocaratuzumab ^§ Otlertuzumab ^§ Onartuzumab ^§ Oportuzumab monatox ^† Parsatuzumab ^§ Pertuzumab Pinatuzumab vedotin ^§ Polatuzumab vedotin ^† Rosmantuzumab Rovalpituzumab tesirine ^† Sacituzumab govitecan ^† Sibrotuzumab ^§ Simtuzumab ^§ Tacatuzumab tetraxetan ^§ Tigatuzumab ^§ Trastuzumab Tucotuzumab celmoleukin ^§ Vandortuzumab vedotin ^§ Vanucizumab ^§ Veltuzumab ^§ Vorsetuzumab mafodotin ^§ CBR96-doxorubicin immunoconjugate PankoMab "-gozu-" (ovarian tumor) Sofituzumab vedotin ^§
Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab ^§
Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin ^† Duvortuxizumab Ontuxizumab ^§
Veterinary ("-tuvet-")	Blontuvetmab ^§ Tamtuvetmab ^§

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-osu-")	Burosumab Denosumab
Humanized ("-sozu-")	Blosozumab Romosozumab

Musculoskeletal ("-mul-")

Human ("-mulu-")	Stamulumab ^†

Circulatory ("-c(i[r])-")

Human ("-ciru-")	Alirocumab Ascrinvacumab Enoticumab Evinacumab ^† Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab Vesencumab
Mouse ("-ciro-")	Biciromab ^‡ Imciromab ^‡
Chimeric ("-cixi-")	Abciximab Volociximab
Humanized ("-cizu-")	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab ^† Caplacizumab Demcizumab Etaracizumab Faricimab ^† Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic ("-ne(u)(r)-")

Human ("-neru-")	Aducanumab ^† Atinumab Elezanumab Erenumab ^† Fasinumab ^† Fulranumab Gantenerumab ^† Opicinumab
Humanized ("-nezu-"/"-neuzu-")	Bapineuzumab ^† Crenezumab ^† Eptinezumab ^† Fremanezumab ^† Galcanezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab ^†
Veterinary ("-nevet-")	Frunevetmab Ranevetmab

Angiogenesis inhibitor ("-anibi-")

Humanized ("-anibizu-")	Ranibizumab

Growth factor ("-gr(o)-")

Human ("-gru-")	Bimagrumab Trevogrumab
Humanized ("-grozu-")	Domagrozumab Landogrozumab

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.